• Explore /
  • Poster
  • / <em>MGMT </em>promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial.

MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial.

Abstract Poster

Authors

Ghazaleh Tabatabai

Ghazaleh Tabatabai

Department of Neurology, University Hospital Zurich, Zurich, Switzerland

Ghazaleh Tabatabai , Wolfgang Wick , Joachim Peter Steinbach , Antje Wick , Oliver Schnell , Peter Hau , Ulrich Herrlinger , Michael Sabel , Hans-Georg Wirsching , Ralf Ketter , Oliver Baehr , Michael Platten , Joerg Tonn , Johannes Huesing , Guido Reifenberger , Michael Weller

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Clinical Trial Registration Number

NCT00941460

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 2015)

DOI

10.1200/jco.2014.32.15_suppl.2015

Abstract #

2015

Poster Bd #

5

Abstract Disclosures

Similar Posters

First Author: Michael Weller

First Author: Paul James Mulholland

First Author: David D. Tran

First Author: Daniela Annenelie Bota